Patents by Inventor Anja Loffler

Anja Loffler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200087410
    Abstract: The present invention pertains to humanized anti-CD40 antibodies having antigen binding properties similar to those of the parent chimeric anti-CD40 antibody and increased Fc? receptor binding affinities. In particular, the present invention is directed to humanized anti-CD40 antibodies which are useful in the treatment of cancer, infections and immunodeficiencies.
    Type: Application
    Filed: March 27, 2018
    Publication date: March 19, 2020
    Applicant: Glycotope GmbH
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Anja LOFFLER, Doreen WEIGELT, Patrick KEHLER
  • Patent number: 9494587
    Abstract: The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the same and to a method of prevention and treatment of core-1 positive disorders using the same. The invention relates to microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: November 15, 2016
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Phillippe Ulsemer, Anja Löffler
  • Patent number: 9051356
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: June 9, 2015
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Löffler, Lars Stöckl
  • Patent number: 8592165
    Abstract: The present invention relates to the field of prevention and treatment of disorders associated with the occurrence of certain carbohydrate epitopes. The present invention relates to the prevention and treatment of carbohydrate epitope positive tumors. The invention relates to formulations and methods for the induction of an effective carbohydrate specific cellular immune response.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: November 26, 2013
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Philippe Ulsemer, Anja Löffler
  • Publication number: 20100303837
    Abstract: The present invention relates to the field of prevention and treatment of disorders associated with the occurrence of certain carbohydrate epitopes. The present invention relates to the prevention and treatment of carbohydrate epitope positive tumors. The invention relates to formulations and methods for the induction of an effective carbohydrate specific cellular immune response.
    Type: Application
    Filed: November 12, 2007
    Publication date: December 2, 2010
    Inventors: Steffen Goletz, Philippe Ulsemer, Anja Löffler
  • Publication number: 20100028947
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Application
    Filed: September 10, 2007
    Publication date: February 4, 2010
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Löffler, Lars Stöckl
  • Patent number: 7575923
    Abstract: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: August 18, 2009
    Assignee: Micromet AG
    Inventors: Bernd Dorken, Gert Riethmuller, Peter Kufer, Ralf Lutterbuse, Ralf Bargou, Anja Loffler
  • Patent number: 7112324
    Abstract: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
    Type: Grant
    Filed: April 21, 1999
    Date of Patent: September 26, 2006
    Assignee: Micromet AG
    Inventors: Bernd Dorken, Gert Riethmuller, Peter Kufer, Ralf Lutterbuse, Ralf Bargou, Anja Loffler
  • Publication number: 20060193852
    Abstract: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
    Type: Application
    Filed: May 5, 2006
    Publication date: August 31, 2006
    Inventors: Bernd Dorken, Gert Riethmuller, Peter Kufer, Ralf Lutterbuse, Ralf Bargou, Anja Loffler